Reconciling ACEA and MCDA: is there a way forward for measuring cost-effectiveness in the U.S. healthcare setting?
Abstract Background The ISPOR Special Task Force (STF) on US Value Assessment Frameworks was agnostic about exactly how to implement the quality-adjusted life year (QALY) as a key element in an overall cost-effectiveness evaluation. But the STF recommended using the cost-per-QALY gained as a startin...
Main Authors: | Bernarda Zamora, Louis P. Garrison, Aig Unuigbe, Adrian Towse |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-03-01
|
Series: | Cost Effectiveness and Resource Allocation |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12962-021-00266-8 |
Similar Items
-
ISPOR 2013: what's new and what's old?
by: Orietta Zaniolo, et al.
Published: (2013-12-01) -
The Great I-QALY Disaster
by: Paul Langley
Published: (2020-08-01) -
EVALUATION OF INGUINAL REPAIR EFFECTIVENESS BASED ON «COST-UTILITY» ANALYSIS
by: A. N. Poborskiy, et al.
Published: (2019-02-01) -
A multi-criteria decision analysis (MCDA) tool for purchasing off-patent oncology medicines in Egypt
by: Baher Elezbawy, et al.
Published: (2022-12-01) -
Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer
by: Peter Paul Yu, et al.
Published: (2019-09-01)